HN2003000401A - Agonistas morfolinicos de la dopamina - Google Patents
Agonistas morfolinicos de la dopaminaInfo
- Publication number
- HN2003000401A HN2003000401A HN2003000401A HN2003000401A HN2003000401A HN 2003000401 A HN2003000401 A HN 2003000401A HN 2003000401 A HN2003000401 A HN 2003000401A HN 2003000401 A HN2003000401 A HN 2003000401A HN 2003000401 A HN2003000401 A HN 2003000401A
- Authority
- HN
- Honduras
- Prior art keywords
- dopamine
- agonists
- morpholinic
- class
- agronists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- VYFYYTLLBUKUHU-WTJCDBBSSA-N 4-(2-amino-1,1-ditritioethyl)benzene-1,2-diol Chemical compound NCC([3H])([3H])C1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-WTJCDBBSSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UNA CLASE DE AGONISTAS DE LA DOPAMINA, MAS PARTICULARMENTE A UNA CLASE DE AGONISTAS QUE SON SELECTIVOS DEL RECEPTOR D3 POR ENCIMA DEL D2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0228787A GB0228787D0 (en) | 2002-12-10 | 2002-12-10 | Morpholine dopamine agonists |
| GB0308460A GB0308460D0 (en) | 2003-04-11 | 2003-04-11 | Morpholine dopamine agonists |
| GB0313606A GB0313606D0 (en) | 2003-06-12 | 2003-06-12 | Morpholine dopamine agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2003000401A true HN2003000401A (es) | 2004-11-23 |
Family
ID=32512061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2003000401A HN2003000401A (es) | 2002-12-10 | 2003-12-09 | Agonistas morfolinicos de la dopamina |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1572214B1 (es) |
| JP (3) | JP3889775B2 (es) |
| KR (1) | KR100796102B1 (es) |
| AP (1) | AP2005003325A0 (es) |
| AR (1) | AR042339A1 (es) |
| AT (1) | ATE460938T1 (es) |
| AU (1) | AU2003302878B2 (es) |
| CA (1) | CA2508262C (es) |
| CO (1) | CO5700781A2 (es) |
| CR (1) | CR7869A (es) |
| CY (1) | CY1110130T1 (es) |
| DE (1) | DE60331769D1 (es) |
| DK (1) | DK1572214T3 (es) |
| EA (1) | EA009589B1 (es) |
| EC (1) | ECSP055850A (es) |
| ES (1) | ES2339767T3 (es) |
| GE (1) | GEP20074272B (es) |
| HN (1) | HN2003000401A (es) |
| HR (1) | HRP20050523A2 (es) |
| IS (1) | IS7843A (es) |
| MA (1) | MA27605A1 (es) |
| MX (1) | MXPA05006151A (es) |
| MY (1) | MY144338A (es) |
| NL (1) | NL1024983C2 (es) |
| NO (1) | NO330143B1 (es) |
| NZ (1) | NZ540505A (es) |
| OA (1) | OA13014A (es) |
| PA (1) | PA8591601A1 (es) |
| PE (1) | PE20040906A1 (es) |
| PL (1) | PL377480A1 (es) |
| PT (1) | PT1572214E (es) |
| RS (1) | RS51442B (es) |
| SI (1) | SI1572214T1 (es) |
| TW (1) | TW200423944A (es) |
| UY (1) | UY28117A1 (es) |
| WO (1) | WO2004052372A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0511533A (pt) * | 2004-05-26 | 2008-01-02 | Pfizer | derivados indazol e indolona e seu uso como medicamento |
| JP4198183B2 (ja) * | 2004-05-27 | 2008-12-17 | ファイザー・インク | 選択的ドーパミンｄ３アゴニストとしてのアミノピリジン誘導体 |
| GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| GB0700786D0 (en) * | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| WO2011146821A2 (en) | 2010-05-21 | 2011-11-24 | Research Triangle Institute | 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence |
| EP2571858B1 (en) * | 2010-05-21 | 2018-06-20 | Research Triangle Institute | Phenylmorpholines and analogues thereof |
| CN105793430B (zh) * | 2013-12-11 | 2020-03-03 | 豪夫迈·罗氏有限公司 | 用于制备手性2-芳基吗啉的方法 |
| GB2543296A (en) | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
| AU2020270992B2 (en) | 2019-04-12 | 2025-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof |
| EP3725768A1 (en) * | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
| CN118684636B (zh) * | 2024-05-31 | 2025-03-11 | 上海优合贝德医药科技有限公司 | 一种4-吗啉-1-苯基巯基-2-丁酮的合成工艺 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB851311A (en) * | 1958-04-02 | 1960-10-12 | Geigy Ag J R | Morpholine compounds and their production |
| GB9108629D0 (en) * | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
-
2003
- 2003-12-02 GE GEAP20038838A patent/GEP20074272B/en unknown
- 2003-12-02 HR HR20050523A patent/HRP20050523A2/hr not_active Application Discontinuation
- 2003-12-02 EA EA200500801A patent/EA009589B1/ru not_active IP Right Cessation
- 2003-12-02 JP JP2005502342A patent/JP3889775B2/ja not_active Expired - Fee Related
- 2003-12-02 OA OA1200500171A patent/OA13014A/en unknown
- 2003-12-02 SI SI200331801T patent/SI1572214T1/sl unknown
- 2003-12-02 AT AT03812639T patent/ATE460938T1/de active
- 2003-12-02 NZ NZ540505A patent/NZ540505A/en not_active IP Right Cessation
- 2003-12-02 EP EP03812639A patent/EP1572214B1/en not_active Expired - Lifetime
- 2003-12-02 AP AP2005003325A patent/AP2005003325A0/xx unknown
- 2003-12-02 MX MXPA05006151A patent/MXPA05006151A/es active IP Right Grant
- 2003-12-02 DK DK03812639.7T patent/DK1572214T3/da active
- 2003-12-02 DE DE60331769T patent/DE60331769D1/de not_active Expired - Lifetime
- 2003-12-02 WO PCT/IB2003/005683 patent/WO2004052372A1/en not_active Ceased
- 2003-12-02 PT PT03812639T patent/PT1572214E/pt unknown
- 2003-12-02 AU AU2003302878A patent/AU2003302878B2/en not_active Ceased
- 2003-12-02 PL PL377480A patent/PL377480A1/pl not_active Application Discontinuation
- 2003-12-02 RS YUP-2005/0445A patent/RS51442B/sr unknown
- 2003-12-02 KR KR1020057010474A patent/KR100796102B1/ko not_active Expired - Fee Related
- 2003-12-02 ES ES03812639T patent/ES2339767T3/es not_active Expired - Lifetime
- 2003-12-02 CA CA002508262A patent/CA2508262C/en not_active Expired - Fee Related
- 2003-12-05 PE PE2003001234A patent/PE20040906A1/es not_active Application Discontinuation
- 2003-12-08 MY MYPI20034690A patent/MY144338A/en unknown
- 2003-12-09 HN HN2003000401A patent/HN2003000401A/es unknown
- 2003-12-09 AR ARP030104524A patent/AR042339A1/es unknown
- 2003-12-09 TW TW092134694A patent/TW200423944A/zh unknown
- 2003-12-10 NL NL1024981A patent/NL1024983C2/nl not_active IP Right Cessation
- 2003-12-10 PA PA20038591601A patent/PA8591601A1/es unknown
- 2003-12-10 UY UY28117A patent/UY28117A1/es not_active Application Discontinuation
-
2005
- 2005-05-12 IS IS7843A patent/IS7843A/is unknown
- 2005-05-26 NO NO20052557A patent/NO330143B1/no not_active IP Right Cessation
- 2005-06-10 MA MA28324A patent/MA27605A1/fr unknown
- 2005-06-10 EC EC2005005850A patent/ECSP055850A/es unknown
- 2005-06-10 CO CO05056566A patent/CO5700781A2/es not_active Application Discontinuation
- 2005-06-10 CR CR7869A patent/CR7869A/es unknown
-
2006
- 2006-06-06 JP JP2006157609A patent/JP3920908B2/ja not_active Expired - Fee Related
- 2006-12-27 JP JP2006352505A patent/JP4624341B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-26 CY CY20101100367T patent/CY1110130T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8576901A1 (es) | Moduladores del receptor de glucocorticoides | |
| CL2021002880S1 (es) | Estuche de auriculares. (divisional solicitud 202000595) | |
| ECSP066334A (es) | Derivados bloqueadores del receptor angiotensina ii | |
| HN2003000401A (es) | Agonistas morfolinicos de la dopamina | |
| TW200501455A (en) | Light emitting device methods (I) | |
| SG155768A1 (en) | Nitride phosphor and production process thereof, and light emitting device | |
| HN2003000094A (es) | Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion. | |
| TW200605416A (en) | Light emitting device processes | |
| TW200503295A (en) | Light emitting devices | |
| SG144146A1 (en) | Adenosine receptor agonists | |
| SV2009002836A (es) | Etiqueta para orejas de animales | |
| CL2008003391A1 (es) | Compuestos derivados de pirrolidinas, moduladores de la funcion del receptor de androgeno (divisional de la solicitud 970-03). | |
| GT200400071A (es) | Compuestos que modulan la actividad de ppar y procedimientos de preparacion | |
| SMP200600024B (it) | 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina | |
| PA8625201A1 (es) | Composiciones de peróxido estabilizadas | |
| MX2020009286A (es) | Antagonistas del receptor de adenosina y usos de los mismos. | |
| PA8654601A1 (es) | Agentes citotoxicos que comprenden taxanos nuevos | |
| GT200600156A (es) | Compuestos heteroaromaticos acilaminobiciclicos y sus usos | |
| PL376130A1 (en) | Controlled releases system containing temozolomide | |
| HN2006004827A (es) | Nueva forma de sal de un agonista de dopamina | |
| CL2015002785A1 (es) | Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario | |
| ATE551036T1 (de) | Kondomverpackung | |
| TW200606985A (en) | Continuous carbon-nanotube filaments for radiation-emitting devices and related methods | |
| SG129364A1 (en) | Semiconductor device | |
| GT200400015A (es) | Agentes de despigmentacion |